Serial ST2 testing in hospitalized patients with acute heart failure.

[1]  J. Cohn,et al.  Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial , 2014, Circulation. Heart failure.

[2]  Thomas J. Wang,et al.  Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. , 2014, JACC. Heart failure.

[3]  P. Benkert,et al.  Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. , 2013, Journal of cardiac failure.

[4]  Anju Bhardwaj,et al.  Soluble Concentrations of the Interleukin Receptor Family Member ST2 and &bgr;-Blocker Therapy in Chronic Heart Failure , 2013, Circulation. Heart failure.

[5]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[6]  A. Jaffe,et al.  Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. , 2013, American heart journal.

[7]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[8]  Jennifer G. Robinson,et al.  ACCF/AHA TASK FORCE MEMBERS , 2013 .

[9]  S. Manzano-Fernández,et al.  Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure , 2012, Cardiology.

[10]  Harlan M Krumholz,et al.  National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. , 2011, JAMA.

[11]  Eric M. Reyes,et al.  Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term OutcomesClinical Perspective , 2011 .

[12]  Eric M. Reyes,et al.  Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes: Data From Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Linked to Medicare Claims , 2011, Circulation. Heart failure.

[13]  D. Brotman,et al.  Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. , 2011, The American journal of cardiology.

[14]  S. Réhman,et al.  Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. , 2010, Clinical chemistry.

[15]  S. Normand,et al.  Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. , 2010, JAMA.

[16]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[17]  Ashley M. Miller,et al.  Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. , 2010, Journal of the American College of Cardiology.

[18]  Richard T. Lee,et al.  Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling , 2009, Circulation. Heart failure.

[19]  M. Picard,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea , 2009, Circulation. Heart failure.

[20]  R. Fitzgerald,et al.  Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. , 2008, Journal of cardiac failure.

[21]  Richard T. Lee,et al.  The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.

[22]  Sharon-Lise T. Normand,et al.  An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure , 2008, Circulation. Cardiovascular quality and outcomes.

[23]  R. Valle,et al.  B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. , 2008, Journal of cardiac failure.

[24]  D. Lloyd‐Jones,et al.  Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.

[25]  S. Schneeweiss,et al.  Repeated hospitalizations predict mortality in the community population with heart failure. , 2007, American heart journal.

[26]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[27]  W. Frishman,et al.  Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure , 2007 .

[28]  Nancy M Albert,et al.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.

[29]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[30]  J. Hollander,et al.  Relationship between obesity and B-type natriuretic peptide levels. , 2004, Archives of internal medicine.

[31]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[32]  Gabriel Thabut,et al.  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.

[33]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[34]  P. Krishnaswamy,et al.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. , 2001, Journal of cardiac failure.

[35]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[36]  M. Radford,et al.  Correlation of the Agency for Health Care Policy and Research congestive heart failure admission guideline with mortality: peer review organization voluntary hospital association initiative to decrease events (PROVIDE) for congestive heart failure. , 1999, Annals of emergency medicine.

[37]  M. Itakura,et al.  Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. , 1999, European journal of biochemistry.

[38]  M. Kinoshita,et al.  Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. , 1998, American heart journal.